565 related articles for article (PubMed ID: 34664301)
1. Diet and gut microbiome in fatty liver and its associated liver cancer.
Pan Y; Zhang X
J Gastroenterol Hepatol; 2022 Jan; 37(1):7-14. PubMed ID: 34664301
[TBL] [Abstract][Full Text] [Related]
2. Dietary cholesterol drives fatty liver-associated liver cancer by modulating gut microbiota and metabolites.
Zhang X; Coker OO; Chu ES; Fu K; Lau HCH; Wang YX; Chan AWH; Wei H; Yang X; Sung JJY; Yu J
Gut; 2021 Apr; 70(4):761-774. PubMed ID: 32694178
[TBL] [Abstract][Full Text] [Related]
3. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
[TBL] [Abstract][Full Text] [Related]
4. The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.
Song Q; Zhang X
Biomedicines; 2022 Feb; 10(3):. PubMed ID: 35327326
[TBL] [Abstract][Full Text] [Related]
5. Gut microbiome in HCC - Mechanisms, diagnosis and therapy.
Schwabe RF; Greten TF
J Hepatol; 2020 Feb; 72(2):230-238. PubMed ID: 31954488
[TBL] [Abstract][Full Text] [Related]
6. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
[TBL] [Abstract][Full Text] [Related]
7. Microbiota-Associated Therapy for Non-Alcoholic Steatohepatitis-Induced Liver Cancer: A Review.
Chen YH; Wu WK; Wu MS
Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32825440
[TBL] [Abstract][Full Text] [Related]
8. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma.
Song Q; Zhang X; Liu W; Wei H; Liang W; Zhou Y; Ding Y; Ji F; Ho-Kwan Cheung A; Wong N; Yu J
J Hepatol; 2023 Dec; 79(6):1352-1365. PubMed ID: 37459922
[TBL] [Abstract][Full Text] [Related]
9. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm.
Ghoshal UC; Goel A; Quigley EMM
Indian J Gastroenterol; 2020 Feb; 39(1):9-21. PubMed ID: 32291578
[TBL] [Abstract][Full Text] [Related]
10. New insights and therapeutic implication of gut microbiota in non-alcoholic fatty liver disease and its associated liver cancer.
Ezzaidi N; Zhang X; Coker OO; Yu J
Cancer Lett; 2019 Sep; 459():186-191. PubMed ID: 31185249
[TBL] [Abstract][Full Text] [Related]
11. The role of the microbiome in NAFLD and NASH.
Kolodziejczyk AA; Zheng D; Shibolet O; Elinav E
EMBO Mol Med; 2019 Feb; 11(2):. PubMed ID: 30591521
[TBL] [Abstract][Full Text] [Related]
12. Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification.
Panasevich MR; Peppler WT; Oerther DB; Wright DC; Rector RS
Physiol Genomics; 2017 Aug; 49(8):385-399. PubMed ID: 28600319
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
14. Current treatment paradigms and emerging therapies for NAFLD/NASH.
Raza S; Rajak S; Upadhyay A; Tewari A; Anthony Sinha R
Front Biosci (Landmark Ed); 2021 Jan; 26(2):206-237. PubMed ID: 33049668
[TBL] [Abstract][Full Text] [Related]
15. The fecal mycobiome in non-alcoholic fatty liver disease.
Demir M; Lang S; Hartmann P; Duan Y; Martin A; Miyamoto Y; Bondareva M; Zhang X; Wang Y; Kasper P; Bang C; Roderburg C; Tacke F; Steffen HM; Goeser T; Kruglov A; Eckmann L; Stärkel P; Fouts DE; Schnabl B
J Hepatol; 2022 Apr; 76(4):788-799. PubMed ID: 34896404
[TBL] [Abstract][Full Text] [Related]
16. Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression.
Mungamuri SK; Vijayasarathy K
Crit Rev Oncog; 2020; 25(1):57-70. PubMed ID: 32865911
[TBL] [Abstract][Full Text] [Related]
17. Gut microbiota, fatty liver disease, and hepatocellular carcinoma.
Chu H; Williams B; Schnabl B
Liver Res; 2018 Mar; 2(1):43-51. PubMed ID: 30416839
[TBL] [Abstract][Full Text] [Related]
18. Microbiota, NASH, HCC and the potential role of probiotics.
Brandi G; De Lorenzo S; Candela M; Pantaleo MA; Bellentani S; Tovoli F; Saccoccio G; Biasco G
Carcinogenesis; 2017 Mar; 38(3):231-240. PubMed ID: 28426878
[TBL] [Abstract][Full Text] [Related]
19. [Microbiome & NASH - partners in crime driving progression of fatty liver disease].
Wree A; Geisler LJ; Tacke F
Z Gastroenterol; 2019 Jul; 57(7):871-882. PubMed ID: 31288283
[TBL] [Abstract][Full Text] [Related]
20. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]